Brief: Prometheus Biosciences Achieves Milestone Payment From Dr. Falk Pharma GmbH Further Validating The Prometheus360™ Platform
21/06/2021 14:18
June 21 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES ACHIEVES MILESTONE PAYMENT FROM DR.
FALK
PHARMA GMBH FURTHER VALIDATING THE PROMETHEUS360™ PLATFORM
* PROMETHEUS BIOSCIENCES INC - IND FOR PR600 EXPECTED IN 3Q
2022
* PROMETHEUS BIOSCIENCES INC - RECEIVES $10 MILLION PAYMENT
TRIGGERED BY SELECTION OF CLINICAL CANDIDATE FOR PR600
Source text for Eikon: ID:nGNX51NtN3
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results